Dashboard
Manage Tickers

ALT


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

altimmune-q3-eps-021-beats-027-estimate-sales-5000k-beat-1250k-estimate
Altimmune Q3 EPS $(0.21) Beats $(0.27) Est...
11/06/2025 12:07:45

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.27) by 2...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

altimmune-completes-patient-enrollment-in-reclaim-phase-2-clinical-trial-evaluating-pemvidutide-in-adults-with-alcohol-use-disorder
Altimmune Completes Patient Enrollment In ...
11/03/2025 12:37:29

Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic opti...

hc-wainwright--co-reiterates-buy-on-altimmune-maintains-12-price-target
HC Wainwright & Co. Reiterates Buy on Alti...
10/20/2025 11:59:45

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price tar...

altimmune-to-present-24-week-data-from-phase-2b-impact-trial-of-pemvidutide-in-metabolic-dysfunction-associated-steatohepatitis-at-the-liver-meeting-2025
Altimmune To Present 24-Week Data From Pha...
10/20/2025 11:36:43

Oral presentation to highlight 24-week efficacy and safety dataPoster to feature results of AI-based analyses of liver fibrosis...

altimmune-stock-a-deep-dive-into-analyst-perspectives-4-ratings
Altimmune Stock: A Deep Dive Into Analyst ...
10/10/2025 12:02:09

hc-wainwright--co-reiterates-buy-on-altimmune-maintains-12-price-target
HC Wainwright & Co. Reiterates Buy on Alti...
10/10/2025 11:04:27

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price tar...

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
09/29/2025 17:35:29

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

radian-group-intel-nanobiotix-crowdstrike-and-other-big-stocks-moving-higher-on-thursday
Radian Group, Intel, Nanobiotix, CrowdStri...
09/18/2025 14:19:12

altimmune-announces-pemvidutide-as-the-only-drug-granted-fast-track-designation-in-alcohol-use-disorder-with-phase-2-reclaim-study-ongoing
Altimmune Announces Pemvidutide As The Onl...
08/19/2025 11:33:43

Pemvidutide is the only drug currently granted Fast Track Designation in AUDRECLAIM, a Phase 2 trial of pemvidutide in AUD, is ...

what-5-analyst-ratings-have-to-say-about-altimmune
What 5 Analyst Ratings Have To Say About A...
08/13/2025 21:01:18

these-analysts-slash-their-forecasts-on-altimmune-following-q2-results
These Analysts Slash Their Forecasts On Al...
08/13/2025 18:57:23

hc-wainwright--co-reiterates-buy-on-altimmune-maintains-12-price-target
HC Wainwright & Co. Reiterates Buy on Alti...
08/13/2025 17:49:53

HC Wainwright & Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price target.

ubs-maintains-buy-on-altimmune-lowers-price-target-to-24
UBS Maintains Buy on Altimmune, Lowers Pri...
08/13/2025 15:51:40

UBS analyst Eliana Merle maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $26 to $24.

b-riley-securities-maintains-buy-on-altimmune-lowers-price-target-to-18
B. Riley Securities Maintains Buy on Altim...
08/13/2025 12:34:39

B. Riley Securities analyst Mayank Mamtani maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $20 ...

altimmune-q2-fy2025-earnings-call-transcript
Altimmune Q2 FY2025 Earnings Call Transcript
08/12/2025 14:18:39

Altimmune Q2 FY2025 earnings call transcript

altimmune-q2-eps-027-beats-032-estimate-sales-5000k-beat-560000-estimate
Altimmune Q2 EPS $(0.27) Beats $(0.32) Est...
08/12/2025 11:03:11

Core News & Articles
Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

uncovering-potential-altimmunes-earnings-preview
Uncovering Potential: Altimmune's Earnings...
08/11/2025 18:02:56

altimmune-names-jerry-durso-chairman-as-company-prepares-for-phase-3-development-of-pemvidutide-in-mash
Altimmune Names Jerry Durso Chairman As Co...
08/11/2025 11:37:48

Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidut...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION